Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis
- PMID: 39325984
- PMCID: PMC11932942
- DOI: 10.1097/HEP.0000000000001046
Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis
Abstract
Background and aims: Alcohol-associated hepatitis (AH) is associated with very high mortality despite abstinence from alcohol; up to 40% of patients die within 6 months of diagnosis. Patients with AH are especially prone to infections, which can lead to multiorgan dysfunction and poorer prognosis.
Approach and results: We performed comprehensive serological profiling of the viral and bacterial infection history of 36 healthy controls, 48 patients with alcohol use disorder, and 224 patients with AH from 2 multicenter observational studies. We used systematic viral and bacterial epitope scanning by VirScan, a phage-display immunoprecipitation and sequencing technology that detects the peptides recognized by antibodies in patient sera, to comprehensively analyze antiviral and antibacterial antibodies and identify serologic biomarkers to predict patient outcomes. We found significant differences in the serological profiles of the 3 populations. The number of serum antibody epitopes in patients with alcohol use disorder during abstinence was increased compared with during active alcohol use. A decreased number and diversity of viral and bacterial antibody targets were detected in the sera of patients with AH, particularly those with a higher Child-Pugh score. In patients with AH, a decrease in the serum antiviral, but not antibacterial, antibody repertoire was associated with decompensation and mortality. Ninety-day mortality in AH could be predicted using a serum viral epitope signature.
Conclusions: Abstinence from alcohol is associated with a significant increase in serum viral and bacterial antibody response. Decreased serum antiviral antibody repertoire is predictive of decompensation of liver disease and mortality in patients with AH.
Copyright © 2024 American Association for the Study of Liver Diseases.
Conflict of interest statement
Conflicts of Interest:
Elizabeth C. Verna received grants from Salix. Juan G. Abraldes consults for 89Bio. AstraZeneca, Boehringer Ingelheim, Boston Pharmaceuticals, and Novo Nordisk. He received grants from Advanz, Cook, and Gilead. Robert S. Brown Jr. consults and received grants from AbbVie, Intercept, and Mirum. He consults for eGenesis, Gilead, and Mallinckrodt. He received grants from Durect. Victor Vargas advises Ipsen. He received grants from Intercept. Debbie L. Shawcross consults and received grants from EnteroBiotix and Norgine. She consults for Apollo Therapeutics, MRM Health, and Satellite Bio. Philippe Mathurin is on the speakers’ bureau for AbbVie and Gilead. Ramon Bataller consults for Boehringer Ingelheim, GlaxoSmithKline, and Novo Nordisk. He is on the speakers’ bureau for AbbVie and Gilead. Bernd Schnabl consults and received grants from Intercept. He consults for Ambys Medicines, Ferring Research Institute, Gelesis, HOST Therabiomics, Mabwell, Patara, Surrozen, and Takeda. He received grants from Axial Biotherapeutics, BiomX, CymaBay, NGM Bio, Prodigy Biotech, and Synlogic Operating Company. He owns stock in Nterica Bio. The remaining authors have no conflicts to report.
Similar articles
-
Glucocorticosteroids for people with alcoholic hepatitis.Cochrane Database Syst Rev. 2017 Nov 2;11(11):CD001511. doi: 10.1002/14651858.CD001511.pub3. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2019 Apr 09;4:CD001511. doi: 10.1002/14651858.CD001511.pub4. PMID: 29096421 Free PMC article. Updated.
-
Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis.Gut. 2024 Dec 10;74(1):103-115. doi: 10.1136/gutjnl-2024-332730. Gut. 2024. PMID: 39033024 Free PMC article.
-
A plasma peptidomic signature reveals extracellular matrix remodeling and predicts prognosis in alcohol-associated hepatitis.Hepatol Commun. 2024 Jul 31;8(8):e0510. doi: 10.1097/HC9.0000000000000510. eCollection 2024 Aug 1. Hepatol Commun. 2024. PMID: 39082970 Free PMC article.
-
Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception.Cochrane Database Syst Rev. 2023 Jan 9;1(1):CD014908. doi: 10.1002/14651858.CD014908.pub2. Cochrane Database Syst Rev. 2023. Update in: Cochrane Database Syst Rev. 2023 May 15;5:CD014908. doi: 10.1002/14651858.CD014908.pub3. PMID: 36622724 Free PMC article. Updated.
-
Antibody tests for identification of current and past infection with SARS-CoV-2.Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2. Cochrane Database Syst Rev. 2022. PMID: 36394900 Free PMC article.
References
-
- Happel KI, Nelson S. Alcohol, immunosuppression, and the lung. Proc Am Thorac Soc 2005;2:428–432. - PubMed
-
- Mbulaiteye SM, Ruberantwari A, Nakiyingi JS, Carpenter LM, Kamali A, Whitworth JA. Alcohol and HIV: a study among sexually active adults in rural southwest Uganda. Int J Epidemiol 2000;29:911–915. - PubMed
-
- Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology 2020;71:306–333. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- I01 BX004594/BX/BLRD VA/United States
- Z01 BC010877/ImNIH/Intramural NIH HHS/United States
- P30 DK120515/DK/NIDDK NIH HHS/United States
- R01 AA024726/AA/NIAAA NIH HHS/United States
- Z01 BC010313/ImNIH/Intramural NIH HHS/United States
- T32 DK007202/DK/NIDDK NIH HHS/United States
- P50 AA011999/AA/NIAAA NIH HHS/United States
- U01 AA026939/AA/NIAAA NIH HHS/United States
- K99 AA031328/AA/NIAAA NIH HHS/United States
- R01 AA020703/AA/NIAAA NIH HHS/United States
- R37 AA020703/AA/NIAAA NIH HHS/United States
- U01 AA021856/AA/NIAAA NIH HHS/United States
LinkOut - more resources
Full Text Sources